Company news

Aptamer Group PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Unilever second Optimer development programme

May 30, 2025

Aptamer Announces New Data at ASGCT

May 15, 2025

Optimer licensing agreements and repeat contracts

May 15, 2025

Alzheimer’s test advanced and royalty agreement

May 6, 2025

Licensing agreed for Optimer as vaccine adjuvant

April 30, 2025

Aptamer Presenting at ASGCT Annual Meeting

April 29, 2025

New Corporate Presentation and Investor Factsheet

April 24, 2025

Interim Results

March 11, 2025

TR-1: Standard form notification of major holdings

February 27, 2025

Notice of Results and Investor Presentation

February 25, 2025

Issue of Equity in lieu of Director fees

January 28, 2025

New Development Contract

December 19, 2024

Grant of Options and Director Fee Shares

December 9, 2024

New Scientific Advisory Board Members

December 6, 2024

Technical Update

December 5, 2024

Results of 2024 Annual General Meeting

November 29, 2024

Agreement extended with genetic medicines customer

November 7, 2024

Commercial Trading Update

November 6, 2024

Full Year Results for the 12mths to 30 June 2024

October 22, 2024

Director Appointment

September 16, 2024

Aptamer extends contract with Unilever

September 3, 2024

Block listing Interim Review

August 27, 2024

Result of General Meeting and Board Changes

August 13, 2024

Supplementary Conditional Placing for £60,000

August 1, 2024

Fundraise to Raise £2.83 million

July 24, 2024

Update on progress in Unilever partnership

July 8, 2024

Agreement to explore Optimer vehicles for siRNA

July 3, 2024

New Contracts Announcement for Optimer Development

June 24, 2024

Partnership with Microsaic Systems

June 14, 2024

New contracts with top ten pharma partners

May 23, 2024

Aptamer and Timser Partnership

May 22, 2024

Holding(s) in Company - REPLACEMENT

April 23, 2024

Top Pharma Company evaluates Optimer for medicine

April 22, 2024

TR-1: Notification of major holdings

April 18, 2024

Aptamer and Kairos Biotech partner for Optimer+

April 18, 2024

Patent submission for Optimer® binders

April 8, 2024

Notice of Interim Results & Investor Presentation

March 22, 2024

Aptamer Progresses Partnership with Unilever

March 11, 2024

R&D progress on new Optimer®+ platform

February 27, 2024

Second Phase of Alzheimer's test with Neuro-Bio

February 22, 2024

Results of 2023 Annual General Meeting

December 15, 2023

Material Agreement with Genetic Medicines Company

December 14, 2023

Full year results for the 12mths ended 30 Jun 2023

November 9, 2023

Grant of Options and Related Party Transaction

October 9, 2023

Placing and Subscription, PDMR Dealing and TVR

September 19, 2023

Contract wins

August 17, 2023

TR-1

August 15, 2023

Update on Strategic Review and Formal Sale Process

July 31, 2023

Fundraise, Proposed Board Changes, RPT, GM Notice

July 31, 2023

Response to Speculation, Strategic Review, Update

July 26, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 9 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.